Media Articles Related to Uroxatral (Alfuzosin)
Benign Prostatic Hyperplasia
Source: MedicineNet doxazosin mesylate Specialty [2016.01.25]
Title: Benign Prostatic Hyperplasia
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 1/25/2016 12:00:00 AM
Benign Prostatic Hyperplasia (Enlarged Prostate) Quiz
Source: MedicineNet Prostatitis Specialty [2012.02.29]
Title: Benign Prostatic Hyperplasia (Enlarged Prostate) Quiz
Category: MedicineNet Quiz
Created: 2/7/2012 3:29:00 PM
Last Editorial Review: 2/29/2012 6:25:09 PM
Ultrasound Noninvasively Detects Bladder Outlet Obstruction
Source: Medscape Radiology Headlines [2016.09.21]
Bladder and prostate ultrasonography noninvasively detects bladder outlet obstruction in men with symptomatic benign prostatic hyperplasia (BPH), researchers from Saudi Arabia report.
Reuters Health Information
Enlarged prostate: Molecular mechanism clue may explain link to inflammation
Source: Prostate / Prostate Cancer News From Medical News Today [2016.09.06]
Discovery of molecular mechanism may explain how inflammation leads to benign prostatic hyperplasia and improve response to androgen-targeted therapies.
Published Studies Related to Uroxatral (Alfuzosin)
Medical expulsive therapy using alfuzosin for patient presenting with ureteral stone less than 10mm: a prospective randomized controlled trial. [2011.07]
OBJECTIVES: To assess the spontaneous passage rate for patients being treated with alfuzosin 10mg daily after presenting with an acute ureteral stone compared with a control group, and to assess the respective pain control status... CONCLUSIONS: MET using alfuzosin SR 10mg daily is effective to enhance the ureteral stone spontaneous passage rate, particularly for upper ureteral stones. Fewer analgesic drugs are consumed and more patients can avoid ureteroscopic lithotripsy and/or extracorporeal shock wave lithotripsy. (c) 2011 The Japanese Urological Association.
The effects of tolterodine extended release and alfuzosin for the treatment of double-j stent-related symptoms. [2009.11]
AIM: To evaluate the effects of tolterodine extended release (ER) and alfuzosin for the treatment of Double-J stent-related lower urinary tract symptoms... CONCLUSIONS: Tolterodine ER and alfuzosin improve stent-related urinary symptoms and body pain.
Prospective randomized trial comparing efficacy of alfuzosin and tamsulosin in management of lower ureteral stones. [2009.04]
OBJECTIVES: To study the efficacy of alfuzosin compared with tamsulosin in the management of lower ureteral stones... CONCLUSIONS: Medical treatment of lower ureteral calculi with tamsulosin and alfuzosin resulted in a significantly increased stone expulsion rate, decreased expulsion time, and a reduced need for analgesic therapy.
Efficacy and safety of combined oral therapy with tadalafil and alfuzosin: an integrated approach to the management of patients with lower urinary tract symptoms and erectile dysfunction. Preliminary report. [2009.02]
INTRODUCTION: Alpha1-blockers (AB) are the first-line monotherapy for lower urinary tract symptoms (LUTS). Phosphodiesterase type 5 (PDE5) inhibitors are the first-line treatment for erectile dysfunction (ED). Numerous studies have supposed a significant association between ED and LUTS, but a causal relationship cannot be established. AIM: The aim was to evaluate the efficacy of a combined therapy with an AB (alfuzosin) and PDE5 inhibitors (tadalafil) in patients with LUTS and ED... CONCLUSIONS: Combined therapy improved ED and LUTS as demonstrated by the significant improvement in uroflowmetry measures and in IPSS and IIEF-EF scores. A significant improvement was also observed in quality of life assessments. The beneficial effects of tadalafil on LUTS similar to the benefits of alfuzosin on ED, although present, were smaller.
Alfuzosin to relieve ureteral stent discomfort: a prospective, randomized, placebo controlled study. [2009.01]
PURPOSE: We assessed the impact of alfuzosin on ureteral stent discomfort... CONCLUSIONS: Alfuzosin improves the patient discomfort associated with ureteral stents by decreasing urinary symptoms and kidney pain but it does not affect the amount of narcotics that patients use while the stent is in place.
Clinical Trials Related to Uroxatral (Alfuzosin)
Use of Alfuzosin in Stone Treatment With ESWL [Recruiting]
Urinary tract stones may form in the kidneys or along the ureteric tracts and when left
untreated, may result in complications such as pain, bleeding, infection and obstruction.
ESWL (extra-corporeal shock wave lithotripsy) has been shown to be an effective and safe
method of treatment for kidney and ureteric stones in-situ. In our centre, ESWL is done on
an outpatient basis with oral pain killers in the weeks following treatment. Patients are
also instructed to increase their fluid intake during this period to expedite the clearance
of stone fragments. There have been studies to show that pain caused by stones is due to
smooth muscle spasm along the ureters, possibly mediated by alpha-receptors. Alpha-blockers
have been shown to improve the expulsion of stones and also improve pain relief when used
alone, or together with ESWL treatment. In our study, we seek to investigate if
alpha-blocker therapy (Alfuzosin) increases stone free rates and improves pain control after
ESWL for renal and ureteric stones. The potential benefits include a higher rate of stone
clearance and better pain control
Alfuzosin Treatment in Children and Adolescents With Hydronephrosis of Neuropathic Etiology [Completed]
Primary objective was to determine efficacy of Alfuzosin in the treatment of children and
adolescents 2-16 years of age with newly diagnosed or progressive hydronephrosis due to
elevated detrusor Leak Point Pressure [LPP] of neuropathic etiology.
Secondary objectives were:
- To investigate the safety and tolerability of alfuzosin 0. 2 mg/kg/day in children and
- To investigate the number of Urinary Tract Infection (UTI) episodes,
- To investigate the pharmacokinetics of Alfuzosin (population kinetics).
Alfuzosin for Voiding Dysfunction in Multiple Sclerosis (MS) [Terminated]
Multiple Sclerosis is often associated with severe functional deficits resulting in a range
of progressive impairments. Approximately 80% of patients have bladder symptoms at the time
of diagnosis and up to 97% will have bladder symptoms during the course of the disease. To
date, the vast majority of treatment has been centered on the use of medications to control
"bladder spasms" and the use of catheters to help patients empty the bladder. There have
been very few studies looking at medications like Alfuzosin that may help in controlling
bladder symptoms in Multiple Sclerosis. Alfuzosin has been shown to significantly improve
voiding symptoms and bladder emptying in patients with prostatic enlargement. There have
been no controlled studies yet to determine whether this treatment helps patients with
Multiple Sclerosis. The purpose of this study is to determine if Alfuzosin improves bladder
symptoms and quality of life in patients with Multiple Sclerosis.
Uroxatral in Men With Benign Prostate Hypertrophy (BPH) and Erectile Dysfunction (ED) [Recruiting]
Uroxatral (alfuzosin) may not only help BPH symptoms but may also improve sexual function in
males with BPH and ED.
Alfuzosin XL Lower Urinary Tract Symptoms Efficacy and Sexuality Study [Completed]
To assess, under daily practice conditions, the safety profile and the efficacy of a new
formulation of alfuzosin administered once daily (Xatral XL) in patients with lower urinary
tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH).
Reports of Suspected Uroxatral (Alfuzosin) Side Effects
Muscular Weakness (3),
Gait Disturbance (3),
Urinary Incontinence (2),
Erectile Dysfunction (2),
Throat Tightness (2),
Cough (2), more >>